Key Takeaways
- Common lung cancer symptoms include a persistent cough, chest pain, shortness of breath, coughing up blood and unexplained weight loss.
- Lung cancer is generally classified into two major types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- Treatment depends on the cancer type, stage, genetic changes and the patient’s overall health.
- Stage 4 lung cancer is advanced disease, but treatments may help control its progression, manage symptoms and extend survival.
- EGFR testing can help identify patients who may benefit from targeted medicines such as osimertinib, gefitinib, erlotinib or afatinib.
- Lung cancer treatment costs in the Philippines vary depending on the hospital, treatment approach, medicines and duration of care.
What Is Lung Cancer?
Lung cancer is one of the most serious cancer diagnoses a person and their family can face. For patients in the Philippines, understanding the early warning signs, cancer stages, available treatments and potential costs can help them make more informed decisions about their care.
Many patients and caregivers search for answers to questions such as: What are the first symptoms of lung cancer? Can lung cancer be cured? What happens in stage 4 lung cancer? Which medicines are used for treatment? And how much does lung cancer treatment cost in the Philippines?
The answers depend on several factors, including the type of lung cancer, its stage, the patient’s overall health and whether specific genetic changes are present in the cancer cells.
This guide explains the important things patients and families should know about lung cancer, with particular attention to diagnosis, treatment options, targeted medicines and access to cancer care in the Philippines.
What Are the First Warning Signs of Lung Cancer?
The early symptoms of lung cancer are not always obvious. Some people experience persistent respiratory problems, while others may have no noticeable symptoms until the disease has progressed.
Recognising unusual or persistent changes in breathing and overall health is important.
Common warning signs include:
- Persistent cough: A cough that does not go away or becomes progressively worse.
- Coughing up blood: Blood or rust-coloured mucus may appear when coughing.
- Chest pain: Discomfort or pain that becomes worse when breathing deeply, coughing or laughing.
- Shortness of breath: Difficulty breathing during everyday activities or even while resting.
- Unexplained weight loss: Losing weight without making changes to diet or exercise.
- Persistent fatigue: Feeling unusually tired or weak without an obvious explanation.
- Hoarseness: A noticeable change in the voice that does not improve.
- Repeated respiratory infections: Frequent bronchitis or pneumonia that keeps returning.
Not everyone with these symptoms has lung cancer. Respiratory infections, asthma and other medical conditions can cause similar problems.
However, persistent symptoms should not be ignored. Anyone experiencing coughing up blood or significant breathing difficulties should seek prompt medical attention.
Early diagnosis can make a difference because treatment options are often broader when lung cancer is identified before it spreads.
What Are the Different Stages of Lung Cancer?
Lung cancer staging describes how far the cancer has developed and whether it has spread beyond its original location.
For non-small cell lung cancer (NSCLC), doctors generally use four main stages, although the staging system also includes more detailed subdivisions.
Stage 1: Early-Stage Lung Cancer
At stage 1, the cancer is relatively small and remains within the lung. It has not spread to nearby lymph nodes.
Surgery may be an option for patients who are medically suitable. Some patients may also receive radiation therapy or additional treatment depending on their individual circumstances.
Stage 2: Lung Cancer With Nearby Involvement
At stage 2, the tumour may be larger or may have spread to nearby lymph nodes or surrounding structures.
Treatment may involve surgery, chemotherapy, targeted therapy in selected cases or a combination of approaches.
Stage 3: Locally Advanced Lung Cancer
At stage 3, the cancer may have spread to lymph nodes or nearby structures within the chest.
Depending on the exact stage and whether surgery is possible, treatment may include chemotherapy, radiation therapy, immunotherapy, targeted therapy or combinations of these treatments.
Stage 4: Advanced or Metastatic Lung Cancer
Stage 4 lung cancer means the disease has spread to distant locations or has developed other features that meet the criteria for metastatic disease.
Common sites of spread include:
- Brain
- Bones
- Liver
- Adrenal glands
- Other areas of the lungs
Treatment generally focuses on controlling cancer growth, reducing symptoms and improving quality of life.
The exact treatment plan depends on the cancer subtype, molecular test results, overall health and previous treatments.
Important: Small cell lung cancer (SCLC) is often classified differently, using limited-stage and extensive-stage categories rather than the same four-stage system commonly used for NSCLC.
What Are the Symptoms of Stage 4 Lung Cancer?
Stage 4 lung cancer can cause symptoms related to the original tumour in the lungs as well as the areas where the cancer has spread.
Possible symptoms include:
- Persistent or worsening cough
- Chest pain and breathing difficulties
- Coughing up blood
- Unexplained weight loss
- Severe fatigue
- Bone or back pain
- Persistent headaches
- Weakness or numbness
- Loss of appetite
The symptoms depend on where the cancer has spread.
For example, cancer that spreads to the bones may cause persistent bone pain. If it spreads to the brain, patients may experience headaches, weakness, balance problems or seizures.
Not every patient experiences the same symptoms, and some people may have relatively few symptoms despite advanced disease.
Doctors use imaging tests, biopsies and other investigations to understand the extent of the cancer and determine suitable treatment options.
How Is Lung Cancer Treated?
Lung cancer treatment depends on several factors, including:
- Type of lung cancer
- Stage at diagnosis
- Genetic or molecular changes in cancer cells
- Patient’s age and general health
- Previous treatments and response to therapy
There is no single treatment that works for every patient.
The main treatment approaches include the following.
Surgery
Surgery involves removing the tumour and, when necessary, nearby lung tissue or lymph nodes.
Â
It is generally considered for selected patients with early-stage or certain locally advanced lung cancers where the tumour can be safely removed.
Chemotherapy
Chemotherapy uses medicines that destroy cancer cells or prevent them from multiplying.
It may be used before surgery, after surgery or as part of treatment for advanced lung cancer.
Some patients receive chemotherapy alongside radiation therapy or immunotherapy.
Radiation Therapy
Radiation therapy uses high-energy radiation to destroy cancer cells.
It may be used to treat tumours in the lungs, manage cancer that has spread to other areas or relieve symptoms such as pain.
Immunotherapy
Immunotherapy helps the immune system recognise and attack cancer cells.
Certain immunotherapy medicines may be used for advanced lung cancer depending on the cancer type and biomarker results.
Targeted Therapy
Targeted therapy uses medicines that act on specific molecular changes involved in cancer growth.Â
Â
For example, some non-small cell lung cancers have changes in the EGFR gene. Patients with particular EGFR mutations may be eligible for EGFR-targeted medicines.
Â
Molecular testing helps doctors identify whether a targeted treatment is appropriate.
What Is the Best Treatment for Lung Cancer?
There is no universally best treatment for lung cancer. The most appropriate option depends on the patient’s diagnosis and the characteristics of the cancer. For some patients with early-stage NSCLC, surgery may offer the best opportunity for long-term disease control. For patients with advanced disease, treatment may involve chemotherapy, immunotherapy or targeted therapy.
For example, patients with certain EGFR mutations may benefit from EGFR-targeted medicines rather than receiving the same treatment approach used for patients without those mutations.
This is why doctors may recommend molecular testing and biomarker analysis before selecting treatment.
Patients should discuss the expected benefits, possible side effects, treatment duration and alternatives with their oncologist.
How Much Does Lung Cancer Treatment Cost in the Philippines?
The cost of lung cancer treatment in the Philippines varies considerably from one patient to another.
There is no single treatment price because expenses depend on the cancer stage, hospital, prescribed medicines, treatment duration and whether additional procedures are required.
Some of the main expenses include:
| Treatment or Service | What Affects the Cost? |
|---|---|
| Initial diagnosis | Consultations, imaging and laboratory tests |
| Lung biopsy | Procedure type and hospital |
| Molecular testing | Type of genetic or biomarker test |
| Surgery | Procedure, hospital stay and recovery |
| Chemotherapy | Medicines, treatment cycles and supportive care |
| Radiation therapy | Treatment technique and number of sessions |
| Targeted therapy | Prescribed medicine, dosage and treatment duration |
| Immunotherapy | Medicine selection and number of treatment cycles |
What About Targeted Therapy Costs?
Targeted cancer medicines can represent a significant part of treatment expenses, particularly when patients require long-term therapy.
Some medicines used for selected EGFR-positive NSCLC patients include:
- Osimertinib
- Gefitinib
- Erlotinib
- Afatinib
Their costs vary according to the medicine, brand or generic option, strength, supplier and availability.
Patients and caregivers should request a treatment cost estimate from their hospital or healthcare provider before starting therapy.
Financial Assistance and Government Support in the Philippines
Patients may also ask about available financial assistance through:
- PhilHealth benefits and applicable cancer care coverage.
- Department of Health hospital assistance programmes.
- Medical Assistance to Indigent and Financially Incapacitated Patients (MAIFIP), subject to eligibility and programme rules.
- Hospital social service departments.
- Applicable charitable and patient assistance programmes.
In 2026, the Philippine Health Technology Assessment Division published recommendations concerning government financing for selected EGFR-targeted medicines, including afatinib, gefitinib and erlotinib for eligible patients.
Government financing decisions and actual patient access depend on the applicable implementation rules, participating facilities and eligibility requirements.
Patients should confirm current coverage and requirements directly with PhilHealth, the relevant government hospital or the appropriate assistance programme.
What Is EGFR-Positive Lung Cancer?
EGFR-positive lung cancer is a type of non-small cell lung cancer in which cancer cells contain specific changes, or mutations, in a gene called the epidermal growth factor receptor (EGFR).
This gene helps regulate how cells grow and divide. Certain EGFR mutations can cause cancer cells to grow and multiply abnormally. Identifying these mutations is important because they can help doctors select targeted treatments.
Why Is EGFR Testing Important?
EGFR testing examines cancer tissue to identify mutations that may influence treatment decisions.
Common mutations include:
- EGFR exon 19 deletions
- EGFR exon 21 L858R mutations
Other less common mutations may also influence treatment selection. Testing may be performed using tumour tissue or other appropriate testing methods depending on the clinical situation.
In the Philippines, the Department of Science and Technology’s Health Technology Assessment Division published a 2026 recommendation supporting government financing of tissue-based EGFR PCR testing for specified NSCLC patient groups.
This is an important development for patients who may benefit from more personalised cancer treatment.
However, not every lung cancer patient has an EGFR mutation. The appropriate tests depend on the cancer diagnosis and the oncologist’s assessment.
What Is the Difference Between Chemotherapy and Targeted Therapy?
Chemotherapy and targeted therapy are both used to treat cancer, but they work differently.
| Feature | Chemotherapy | Targeted Therapy |
|---|---|---|
| How it works | Attacks rapidly dividing cells | Targets specific molecular changes involved in cancer growth |
| Treatment selection | Depends on cancer type and clinical factors | Often requires molecular or biomarker testing |
| Administration | Often intravenous, sometimes oral | Depends on the medicine; many are oral |
| Side effects | May affect healthy rapidly dividing cells | Side effects depend on the specific target and medicine |
| Suitability | Used across many cancer types | Only suitable when relevant treatment targets are present |
Chemotherapy and targeted therapy are both used to treat cancer, but they work differently. Chemotherapy may be recommended for different types and stages of lung cancer. Targeted therapy is more specific and may be appropriate when testing identifies a particular mutation or molecular alteration. For example, osimertinib is an EGFR-targeted medicine used for selected patients with EGFR-mutated NSCLC.
Neither treatment is automatically better for every patient. The choice depends on the cancer’s characteristics and the treatment goals.
What Medicines Are Used to Treat Lung Cancer?
Several medicines are used to treat lung cancer. The appropriate medicine depends on whether the patient has NSCLC or SCLC, the cancer stage and any identified molecular changes.
Some medicines used in selected NSCLC treatment plans include the following.
Osimertinib
Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) used for specific EGFR-mutated NSCLC cases.
It is commonly associated with treatment involving EGFR exon 19 deletions and exon 21 L858R mutations, depending on the treatment setting.
Gefitinib
Gefitinib is another EGFR-targeted medicine used for selected patients with locally advanced or metastatic EGFR-mutated NSCLC.
It works by inhibiting the EGFR signalling pathway involved in cancer cell growth.
Erlotinib
Erlotinib is an EGFR-targeted medicine used in certain patients with advanced NSCLC carrying activating EGFR mutations.
Its suitability depends on the patient’s mutation profile and treatment history.
Afatinib
Afatinib is an EGFR-targeted medicine used for selected patients with advanced or metastatic EGFR-positive NSCLC.
It works by blocking signalling through specific members of the ErbB receptor family.
Other Lung Cancer Medicines
Depending on the diagnosis, treatment may also involve:
- Carboplatin
- Cisplatin
- Pemetrexed
- Paclitaxel
- Docetaxel
- Pembrolizumab
- Atezolizumab
- Durvalumab
These medicines have different roles, mechanisms and eligibility requirements.
Important: Osimertinib, gefitinib, erlotinib and afatinib are not interchangeable. They should only be used when prescribed for an appropriate clinical indication. Patients should never select or change cancer medicines without consulting their oncologist.
How Long Can Someone Live With Stage 4 Lung Cancer?
This is one of the most difficult questions for patients and their families. There is no fixed life expectancy for someone diagnosed with stage 4 lung cancer. Some patients respond well to treatment and live for several years, while others experience more aggressive disease.
Survival depends on several factors:
- Whether the cancer is NSCLC or SCLC.
- The specific subtype and genetic mutations.
- Where the cancer has spread.
- The patient’s general health.
- Whether the cancer responds to treatment.
- The availability of suitable treatment options.
Advances in targeted therapy and immunotherapy have expanded treatment options for certain patients with advanced lung cancer.
For example, patients with specific EGFR mutations may have access to targeted treatments that can help control disease progression.
However, individual outcomes vary significantly. An oncologist who understands the patient’s diagnosis, test results and treatment response is best placed to discuss prognosis.
It is also important to remember that treatment is not only about survival. Managing pain, improving breathing, maintaining daily activities and supporting emotional well-being are important parts of cancer care.
Lung Cancer Treatment and Medicine Availability in the Philippines
Access to appropriate cancer medicines is an important concern for patients and caregivers in the Philippines.
After receiving a diagnosis, families may research different treatment options, prescribed medicines, available strengths, medicine prices and pharmaceutical suppliers.
Specialty medicines used in lung cancer treatment may include EGFR-targeted therapies such as osimertinib, gefitinib, erlotinib and afatinib.
However, availability can vary by product, manufacturer, supplier and applicable local regulations.
Pharmaceutical Sourcing Assistance from LetsMeds
LetsMeds is an India-based pharmaceutical supplier supporting international medicine sourcing enquiries, including requests involving specialty and pharmaceutical medicines. For patients, caregivers and other eligible buyers in the Philippines who are researching prescribed specialty medicines, LetsMeds can provide information about sourcing options, product availability and pricing enquiries. The company focuses on pharmaceutical supply and international sourcing rather than providing medical diagnosis or treatment recommendations.
Frequently Asked Questions About Lung Cancer
Some early-stage lung cancers can be treated with curative intent, particularly when the tumour can be completely removed or treated with appropriate radiation therapy. Advanced lung cancer is more difficult to cure, although treatment may help control the disease and improve survival.
A persistent cough that does not improve or becomes worse is one of the common symptoms. Other warning signs include chest pain, coughing up blood, breathlessness and unexplained weight loss.
Yes. Stage 4 lung cancer can be treated using chemotherapy, targeted therapy, immunotherapy, radiation therapy and supportive care, depending on the cancer type and individual patient factors.
Non-small cell lung cancer (NSCLC) is more common than small cell lung cancer (SCLC). These types differ in their biological behaviour and treatment approaches.
Â
No. EGFR testing is particularly relevant for selected patients with NSCLC, especially non-squamous tumours. The oncologist determines which molecular and biomarker tests are appropriate.
Both are EGFR-targeted medicines used for selected patients with EGFR-mutated NSCLC. They differ in their pharmacological properties, treatment indications and clinical use. The appropriate choice depends on the patient’s mutation profile and treatment setting.
There is no single price applicable to all patients. Costs depend on the brand or generic product, strength, supplier, availability and treatment duration. Patients should obtain current quotations and discuss coverage options with their healthcare provider.
Â
Yes. Although smoking is a major risk factor, lung cancer can also occur in people who have never smoked. Other risk factors include secondhand smoke, radon exposure, air pollution and certain occupational exposures.
Yes. Advanced lung cancer can spread to the brain, bones, liver, adrenal glands and other organs. Symptoms depend on the location of the spread.
Â
Patients can consult their oncologist, hospital pharmacy and authorised pharmaceutical suppliers to understand available treatment medicines, product options and applicable access requirements.
References & Authoritative Sources
- National Cancer Institute (NCI):
https://www.cancer.gov/types/lung - American Cancer Society:Â
https://www.cancer.org/cancer/types/lung-cancer.html - World Health Organization (WHO):Â
https://www.who.int/news-room/fact-sheets/detail/cancer - National Comprehensive Cancer Network (NCCN):Â
https://www.nccn.org/guidelines/category_1 - Philippine Department of Science and Technology – Health Technology Assessment Division:Â
https://hta.dost.gov.ph/ - PhilHealth:Â
https://www.philhealth.gov.ph/ - US Food and Drug Administration (FDA):Â
https://www.accessdata.fda.gov/scripts/cder/daf/
This article is intended for educational and informational purposes only. It does not replace professional medical advice, diagnosis or treatment. Lung cancer diagnosis and treatment decisions should be made by qualified healthcare professionals based on the patient’s medical condition, pathology findings and appropriate molecular testing.
Do not start, stop or change any cancer medicine without consulting an oncologist. Medicine indications, availability, pricing and regulatory requirements may change over time.
